Can-Fite Announces New Findings on Namodenoson's Dual Anti-Cancer and Liver Protective Effects
Can-Fite Announces New Findings on Namodenoson's Dual Anti-Cancer and Liver Protective Effects
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating anti-inflammatory, anti-cancer, metabolic and insulin resistance. Namodenoson increases adiponectin production in pre-clinical studies and in humans.
生物技術公司Can-Fite BioPharma Ltd.（紐交所：CANF)（特拉維夫證券交易所：CANF)，正在推進專有小分子藥物產品管道，用於治療癌症和炎症性疾病。今天宣佈，公司的科學家成功找到了一個突破性的發現，證明抗癌和肝保護效果是通過信號蛋白脂聯素轉導的。這種非常重要的陽性細胞因子在調節抗炎、抗癌、代謝和胰島素阻抗方面起着關鍵的作用。Namodenoson在臨床前研究和人體實驗中增加了脂聯素的產生。
The data will be presented at the 20th Annual Congress of International Drug Discovery Science & Technology, China Branch (IDDST-2024), September 12-14, Shanghai, China. This conference will host 300 leading scientists from the academia and industry worldwide to discuss the latest developments in drug discovery and therapy.
數據將在2024年9月12日至14日於中國上海召開的第20屆國際藥物發現科技大會（IDDST-2024）上展示。此次會議將有來自全球學術界和行業領先科學家300人蔘加，討論藥物研發和治療的最新進展。
"We are very much enthused by the breakthrough findings that explain the dual mechanism of Namodenoson working as an anti-cancer agent in the liver and also inducing a liver protective effect," stated Dr. Pnina Fishman, Can-Fite CSO & Chairperson.
“我們對解釋Namodenoson作爲肝臟抗癌劑和誘導肝臟保護效應的雙重機制的突破性發現非常興奮，”Can-Fite CSO兼主席Pnina Fishman博士表示。
Namodenoson is currently being evaluated in LiverationTM, a pivotal Phase III study for advanced liver cancer that has been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and also in a Phase IIb study in patients with MASH.
Namodenoson目前正在進行LiverationTM臨床III期研究,以治療晚期肝癌，該研究已獲得美國食品藥品監督管理局（FDA）和歐洲藥品管理局（EMA）的批准，並且還在MASH患者的IIb期研究中。
譯文內容由第三人軟體翻譯。